Editas' CRISPR-based eye therapy proves safe, but the jury's still out on whether it works

Max Gelman

Senior Editor

Researchers at Editas Medicine revealed long-anticipated data for their CRISPR gene editing program Wednesday morning, the second-ever batch of human results for in vivo administration …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Editas' CRISPR-based eye therapy proves safe, but the jury's still out on whether it works

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

How AI can address ongoing challenges in the life sciences industry

Ed­i­tas' CRISPR-based eye ther­a­py proves safe, but the ju­ry's still out on whether it works

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Editas' CRISPR-based eye therapy proves safe, but the jury's still out on whether it works